TABLE 1

Patient characteristics and measurements

General characteristics
 Age years51±14
 Sex
  Female49
  Male13
 6MWD m459±151
 NT-proBNP ng·L−1363 (122–1150)
Disease type
 Idiopathic/hereditary PAH43
 PAH associated with connective tissue disease13
 HIV-associated PAH1
 Pulmonary veno-occlusive disease1
 Chronic thromboembolic pulmonary hypertension4
Treatment at time of assessment
 None12
 Mono therapy11
 Double therapy34
 Triple therapy5
Right heart catheterisation
 HR beats·min−175±11
 Stroke volume mL77±25
 mPAP mmHg48±12
 mRAP mmHg8±5
SvO2 %68±10
 PAWP mmHg9±3
 PVR dyn·s·cm−5518 (362–1417)
 CO L·min−15.8±1.9
Cardiac magnetic resonance imaging
 HR beats·min−175±13
 Stroke volume mL57±16
 RVEDV mL163±64
 RVESV mL101±64
 RVEF %42±14
 Maximal RA size cm230±10
 LVEDV mL104±30
 LVESV mL40±18
 LVEF %63±9

Data are presented as mean±sd or median (interquartile range) dependent on normal distribution, or as n. 6MWD: 6-min walk distance; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAH: pulmonary arterial hypertension; HR: heart rate; mPAP: mean pulmonary arterial pressure; mRAP: mean right atrial pressure; SvO2: mixed venous oxygen saturation; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance; CO: cardiac output; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; RA: right atrium; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LVEF: left ventricular ejection fraction.